Thompson Peter A. 4

4 · Corvus Pharmaceuticals, Inc. · Filed Jan 30, 2026

Research Summary

AI-generated summary of this filing

Updated Jan 30, 2026

Corvus (CRVS) 10% Owner Peter A. Thompson Exercises Options (~$1.12M)

What Happened
Peter A. Thompson (identified as a 10% owner) exercised multiple stock option tranches on January 28, 2026, resulting in the acquisition of 210,000 common shares of Corvus Pharmaceuticals (CRVS). The exercises involved a range of strike prices (from $0.96 up to $15.00) and required aggregate cash payment of approximately $1.12 million. Corresponding derivative interests (the options) were recorded as disposed at $0 consideration (i.e., the options were converted into shares).

Key Details

Transaction date: January 28, 2026 (Form 4 filed Jan 30, 2026).
Shares acquired: 210,000 common shares (sum of one 30,000 tranche and twelve 15,000 tranches).
Cash paid (aggregate): ~$1,119,374 (reported exercise prices include $15.00, $9.70, $12.50, $3.61, $2.00, $3.27, $2.74, $2.60, $0.99, $0.96, $2.49, $1.64, $2.12).
Dispositions: 210,000 derivative securities shown disposed at $0.00 (reflecting conversion of options into shares). Transaction code: M = option exercise/conversion.
Shares owned after transaction: not specified in the provided excerpt.
Footnotes of note: F1–F3 indicate Thompson is obligated to transfer the securities or economic benefits to OrbiMed Advisors LLC / OrbiMed Capital GP V LLC for delivery to OrbiMed Private Investments V, LP (OPI V), and disclaims beneficial ownership except for any pecuniary interest. F2 notes Thompson is a member of OrbiMed Advisors. This means the activity relates to OrbiMed’s institutional position rather than a conventional executive cash buy/sell.
Filing timeliness: No late-filing flag indicated (filed Jan 30 for Jan 28 transactions).

Context

M-code (option exercise): Thompson exercised vested options and received underlying common shares; the options were extinguished (reported as disposed at $0). This was an exercise, not an open-market purchase or sale of shares.
Institutional note: Because of transfer/assignment provisions and the Form 4 footnotes, these actions appear tied to OrbiMed’s management/holding structure (institutional), not necessarily an individual personal investment decision.

Insider Transaction Report

Form 4

Period: 2026-01-28

Corvus Pharmaceuticals, Inc.CRVS

Thompson Peter A.

Director10% Owner

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-28$15.00/sh+30,000$450,000→ 30,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$9.70/sh+15,000$145,500→ 45,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$12.50/sh+15,000$187,500→ 60,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$3.61/sh+15,000$54,150→ 75,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$2.00/sh+15,000$30,000→ 90,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$3.27/sh+15,000$49,050→ 105,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$2.74/sh+15,000$41,100→ 120,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$2.60/sh+15,000$39,000→ 135,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$0.99/sh+15,000$14,849→ 150,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$0.96/sh+15,000$14,475→ 165,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$2.49/sh+15,000$37,350→ 180,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$1.64/sh+15,000$24,600→ 195,000 total
Exercise/Conversion
Common Stock
[F1]
2026-01-28$2.12/sh+15,000$31,800→ 210,000 total
Exercise/Conversion
Stock Option (Right to Buy)
[F4][F1]
2026-01-28−30,000→ 0 total
Exercise: $15.00Exp: 2026-03-22→ Common Stock (30,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F5][F1]
2026-01-28−15,000→ 0 total
Exercise: $9.70Exp: 2027-06-08→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F6][F1]
2026-01-28−15,000→ 0 total
Exercise: $12.50Exp: 2028-06-21→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F7][F1]
2026-01-28−15,000→ 0 total
Exercise: $3.61Exp: 2029-06-20→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F8][F1]
2026-01-28−15,000→ 0 total
Exercise: $2.00Exp: 2030-03-19→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F9][F1]
2026-01-28−15,000→ 0 total
Exercise: $3.27Exp: 2030-06-09→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F10][F1]
2026-01-28−15,000→ 0 total
Exercise: $2.74Exp: 2031-06-15→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F11][F1]
2026-01-28−15,000→ 0 total
Exercise: $2.60Exp: 2031-09-09→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F12][F1]
2026-01-28−15,000→ 0 total
Exercise: $0.99Exp: 2032-06-15→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F13][F1]
2026-01-28−15,000→ 0 total
Exercise: $0.96Exp: 2032-08-11→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F14][F1]
2026-01-28−15,000→ 0 total
Exercise: $2.49Exp: 2033-06-15→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F15][F1]
2026-01-28−15,000→ 0 total
Exercise: $1.64Exp: 2033-12-06→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F16][F1]
2026-01-28−15,000→ 0 total
Exercise: $2.12Exp: 2024-06-13→ Common Stock (15,000 underlying)

Holdings

Common Stock
[F2][F3]
(indirect: See Footnotes)
8,609,091

Footnotes (16)

[F1]Pursuant to an agreement with OrbiMed Advisors LLC ("OrbiMed Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
[F10]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F11]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.
[F12]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F13]The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
[F14]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F15]The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
[F16]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F2]These securities are held of record by OPI V. GP V is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.
[F3]Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
[F4]The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
[F5]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F6]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F7]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
[F8]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.
[F9]The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Signature

/s/ Peter A. Thompson|2026-01-30

Documents

1 file

4
ownership.xmlPrimary